Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug

We recently published 14 Stocks on Jim Cramer’s Radar.  Novartis AG (NYSE:NVS) is one of the stocks on Jim Cramer's radar.

Pharmaceutical firm Novartis AG (NYSE:NVS)’s shares are up by 44% over the past year and by 7.6% year-to-date. The tail end of 2025 saw several analysts discuss the firm. For instance, Morgan Stanley upgraded the shares to Overweight and increased the share price target to CHF110 from CHF108. The bank pointed out that Novartis AG (NYSE:NVS)’s shares had suffered excessively after the firm’s third-quarter earnings, and the selloff was driven by legacy products. Consequently, the troubles with the older products had been fully reflected in the stock. TD Cowen discussed the firm in November as it reiterated a Hold rating and a $140 share price target. According to the financial firm, some of Novartis AG (NYSE:NVS)’s growth projections might be a bit too optimistic. Cramer has also discussed the firm over the past few months. According to him, while the pharmaceutical company’s weight loss pill marks a key early mover advantage, medical professionals will be hesitant to advise patients to switch over to it. In a recent tweet, he focused on the firm’s cancer drug Pluvicto. Cramer has focused on cancer treatments from Johnson & Johnson and has been optimistic about the firm because of them. Consequently, it was unsurprising that he remarked: “Pluvicto strong– Novartis very strong buy.”

While we acknowledge the potential of NVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.